OBJECTIVES: The objectives of this study were to estimate national seroprevalence of herpes simplex virus type 1 (HSV-1), describe trends in seroprevalence, and examine correlates of infection. GOAL: The goal of this study was to measure the burden of HSV-1 infection in the U.S. population. STUDY: We tested serum samples for HSV-1 antibody and analyzed questionnaire data collected for the second and third National Health and Nutrition Surveys (NHANES II, 1976-80; NHANES III, 1988-94). Seroprevalence estimates were weighted to represent the total U.S. population. RESULTS: At the time of NHANES III, two thirds (68%) of the U.S. population 12 years and older had HSV-1 antibody. Prevalence increased with age and varied by race/ethnicity; the majority of persons in all race/ethnic groups were HSV-1-seropositive by age 30. Overall, the national seroprevalence of HSV-1 decreased nonsignificantly by 2% in the years between NHANES II and III; decreases in HSV-1 seroprevalence in some population subgroups were balanced by increases in other groups. CONCLUSIONS: There was no overall change in the seroprevalence of HSV-1 in the U.S. population between NHANES II and III.
OBJECTIVES: The objectives of this study were to estimate national seroprevalence of herpes simplex virus type 1 (HSV-1), describe trends in seroprevalence, and examine correlates of infection. GOAL: The goal of this study was to measure the burden of HSV-1 infection in the U.S. population. STUDY: We tested serum samples for HSV-1 antibody and analyzed questionnaire data collected for the second and third National Health and Nutrition Surveys (NHANES II, 1976-80; NHANES III, 1988-94). Seroprevalence estimates were weighted to represent the total U.S. population. RESULTS: At the time of NHANES III, two thirds (68%) of the U.S. population 12 years and older had HSV-1 antibody. Prevalence increased with age and varied by race/ethnicity; the majority of persons in all race/ethnic groups were HSV-1-seropositive by age 30. Overall, the national seroprevalence of HSV-1 decreased nonsignificantly by 2% in the years between NHANES II and III; decreases in HSV-1 seroprevalence in some population subgroups were balanced by increases in other groups. CONCLUSIONS: There was no overall change in the seroprevalence of HSV-1 in the U.S. population between NHANES II and III.
Authors: Christopher R Cotter; Won-keun Kim; Marie L Nguyen; Jacob S Yount; Carolina B López; John A Blaho; Thomas M Moran Journal: J Virol Date: 2011-09-21 Impact factor: 5.103
Authors: Mina Kalantari-Dehaghi; Sookhee Chun; Aziz Alami Chentoufi; Jozelyn Pablo; Li Liang; Gargi Dasgupta; Douglas M Molina; Algis Jasinskas; Rie Nakajima-Sasaki; Jiin Felgner; Gary Hermanson; Lbachir BenMohamed; Philip L Felgner; D Huw Davies Journal: J Virol Date: 2012-02-08 Impact factor: 5.103
Authors: Hayley D Mark; Joy P Nanda; Jessica Roberts; Anne Rompalo; Johan H Melendez; Jonathan Zenilman Journal: Sex Transm Dis Date: 2007-09 Impact factor: 2.830
Authors: Konasale M Prasad; Shaun M Eack; Matcheri S Keshavan; Robert H Yolken; Satish Iyengar; Vishwajit L Nimgaonkar Journal: Schizophr Bull Date: 2012-03-23 Impact factor: 9.306
Authors: J J Xu; M K Smith; J Chu; G W Ding; D F Chang; G B Sharp; H Z Qian; L Lu; A M Bi; N Wang Journal: Int J STD AIDS Date: 2012-09 Impact factor: 1.359
Authors: Mira Katan; Yeseon Park Moon; Myunghee Cho Paik; Ralph L Sacco; Clinton B Wright; Mitchell S V Elkind Journal: Neurology Date: 2013-03-26 Impact factor: 9.910
Authors: Christopher R Cotter; Marie L Nguyen; Jacob S Yount; Carolina B López; John A Blaho; Thomas M Moran Journal: PLoS One Date: 2010-02-18 Impact factor: 3.240